Individuals with co-occurring substance use and anxiety disorders can present as a diagnostic challenge. This article aims to provide clinicians with an overview of practical approaches to assessment and treatment of this common co-morbidity.
Conclusions:
A comprehensive assessment can assist in formulating a holistic management plan that incorporates adapted psychological and pharmacological therapies to address both substance use and anxiety disorders in an integrated manner.
TeessonMSladeTMillsK. Comorbidity in Australia: findings of the 2007 national survey of mental health and wellbeing. Aust N Z J Psychiatry2009; 43: 606–614.
2.
MillsKLTeessonMRossJ. Trauma, PTSD, and substance use disorders: findings from the Australian National Survey of Mental Health and Well-Being. Am J Psychiatry2006; 163: 652–658.
3.
BurnsLTeessonM. Alcohol use disorders comorbid with anxiety, depression and drug use disorders: Findings from the Australian National Survey of Mental Health and Well Being. Drug Alcohol Depen2002; 68: 299–307.
4.
MillsKLLynskeyMTeessonM. Post-traumatic stress disorder among people with heroin dependence in the Australian treatment outcome study (ATOS): prevalence and correlates. Drug Alcohol Depend2005; 77: 243–249.
5.
LecomteTMueserKTMacEwanWG. Profiles of individuals seeking psychiatric help for psychotic symptoms linked to methamphetamine abuse – baseline results from the MAPS (methamphetamine and psychosis study). Ment Health Subst Use: Dual Diagnosis. 2010; 3: 168–181.
6.
BurnsLTeessonMO’NeillK. The impact of comorbid anxiety and depression on alcohol treatment outcomes. Addiction2005; 100: 787–796.
7.
KushnerMGAbramsKBorchardtC. The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings. Clin Psychol Rev2000; 20: 149–171.
8.
BruceSEYonkersKAOttoMW. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry2005; 162: 1179–1187.
9.
RobinsonJSareenJCoxBJ. Role of self-medication in the development of comorbid anxiety and substance use disorders: a longitudinal investigation. Arch Gen Psychiatry2011; 68: 800–807.
10.
LiangWChikritzhsTLentonS. Affective disorders and anxiety disorders predict the risk of drug harmful use and dependence. Addiction2011; 106: 1126–1134.
11.
MooreTHZammitSLingford-HughesA. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet2007; 370: 319–328.
12.
HidesLLubmanDICosgraveEM. Motives for substance use among young people seeking mental health treatment. Early Interv Psychiatry2008; 2: 188–194.
13.
StaigerPMelvilleFHidesL. Can emotion-focused coping help explain the link between posttraumatic stress disorder severity and triggers for substance use in young adults?J Subst Abuse Treat2009; 36: 220–226.
14.
GoodwinRDHamiltonSP. Lifetime comorbidity of antisocial personality disorder and anxiety disorders among adults in the community. Psychiatry Res2003; 117: 159–166.
15.
BradyKTTolliverBKVerduinML. Alcohol use and anxiety: diagnostic and management issues. Am J Psychiatry2007; 164: 217–221; quiz 372.
16.
LijffijtMHuKSwannAC. Stress modulates illness-course of substance use disorders: a translational review. Front Psychiatry2014; 5: 83.
17.
BakerALThorntonLKHilesS. Psychological interventions for alcohol misuse among people with co-occurring depression or anxiety disorders: a systematic review. J Affect Disord2012; 139: 217–229.
18.
NajavitsLMWeissRDShawSR. ‘Seeking safety’: outcome of a new cognitive-behavioral psychotherapy for women with posttraumatic stress disorder and substance dependence. J Trauma Stress1998; 11: 437–456.
19.
BookSWThomasSERandallPK. Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. J Anxiety Disord2008; 22: 310–318.
20.
PetrakisILPolingJLevinsonC. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry2005; 57: 1128–1137.
21.
Lingford-HughesARWelchSPetersL. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol2012; 26: 899–952.
22.
PosternakMAMuellerTI. Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence. Am J Addict2001; 10: 48–68.
23.
BestDWilsonAReedM. Alprazolam and wider benzodiazepine misuse in Australia – sources of supply and evidence of harms. Aust N Z J Psychiatry2013; 47: 94–95.
24.
HeilbronnCLloydBMcElweeP. Trends in quetiapine use and non-fatal quetiapine-related ambulance attendances. Drug Alcohol Rev2013; 32: 405–411.
